Published in Arterioscler Thromb Vasc Biol on April 01, 2001
Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest (2004) 3.63
Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem (2009) 1.42
The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes. Lipids Health Dis (2016) 1.38
The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res (2010) 1.36
Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) (2014) 1.34
HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol (2010) 1.32
Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum (2009) 1.31
Oxidative risk for atherothrombotic cardiovascular disease. Free Radic Biol Med (2009) 1.24
Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum (2012) 1.20
Unraveling the complexities of the HDL lipidome. J Lipid Res (2013) 1.19
Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis? J Lipid Res (2012) 1.19
HDL as a biomarker, potential therapeutic target, and therapy. Diabetes (2009) 1.19
Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice. J Biol Chem (2010) 1.17
Generating genetic risk scores from intermediate phenotypes for use in association studies of clinically significant endpoints. Ann Hum Genet (2005) 1.13
Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther (2008) 1.12
High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. Arterioscler Thromb Vasc Biol (2012) 1.11
HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J Lipid Res (2008) 1.09
High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res (2013) 1.09
Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol (2012) 1.07
Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am J Physiol Heart Circ Physiol (2009) 1.07
Multiple indications for anti-inflammatory apolipoprotein mimetic peptides. Curr Opin Investig Drugs (2008) 1.06
Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther (2009) 1.05
Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response. Cholesterol (2010) 1.02
Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol (2015) 1.00
Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterol (2009) 0.99
Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther (2010) 0.98
Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J Med Chem (2013) 0.98
Levels of high-density lipoprotein cholesterol (HDL-C) among children with steady-state sickle cell disease. Lipids Health Dis (2010) 0.95
Biological properties of apolipoprotein a-I mimetic peptides. Curr Atheroscler Rep (2010) 0.95
The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid Redox Signal (2011) 0.95
Calciphylaxis in pediatric end-stage renal disease. Pediatr Nephrol (2005) 0.95
Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids Health Dis (2010) 0.95
Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial (2009) 0.94
Apolipoprotein A-I attenuates palmitate-mediated NF-κB activation by reducing Toll-like receptor-4 recruitment into lipid rafts. PLoS One (2012) 0.93
Reverse cholesterol transport pathway in experimental chronic renal failure. Am J Nephrol (2009) 0.92
Excess coronary artery disease risk in South Asian immigrants: can dysfunctional high-density lipoprotein explain increased risk? Vasc Health Risk Manag (2008) 0.92
Low HDL levels and the risk of death, sepsis and malignancy. Clin Res Cardiol (2007) 0.91
Why targeting HDL should work as a therapeutic tool, but has not. J Cardiovasc Pharmacol (2013) 0.90
A novel anti-atherogenic role for COX-2--potential mechanism for the cardiovascular side effects of COX-2 inhibitors. Prostaglandins Other Lipid Mediat (2007) 0.89
Interaction of HDL cholesterol concentrations on the relationship between physical function and inflammation in community-dwelling older persons. Age Ageing (2009) 0.88
Hepatitis B virus infection and coronary atherosclerosis: results from a population with relatively high prevalence of hepatitis B virus. World J Gastroenterol (2005) 0.88
Obesity and weight loss result in increased adipose tissue ABCG1 expression in db/db mice. Biochim Biophys Acta (2011) 0.88
The inverse association of serum HBV DNA level with HDL and adiponectin in chronic hepatitis B infection. Virol J (2010) 0.87
HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders. Curr Pharm Des (2010) 0.87
Eggs modulate the inflammatory response to carbohydrate restricted diets in overweight men. Nutr Metab (Lond) (2008) 0.87
Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids Health Dis (2010) 0.83
Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. Open Cardiovasc Med J (2007) 0.82
Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheumatol Rep (2012) 0.81
Quercetin and ethanol attenuate the progression of atherosclerotic plaques with concomitant up regulation of paraoxonase1 (PON1) gene expression and PON1 activity in LDLR-/- mice. Alcohol Clin Exp Res (2010) 0.80
A high throughput biochemical fluorometric method for measuring lipid peroxidation in HDL. PLoS One (2014) 0.80
Effect of oxidation on the structure of human low- and high-density lipoproteins. Biophys J (2014) 0.77
Low high-density lipoprotein cholesterol level is a significant risk factor for development of type 2 diabetes: Data from the Hawaii-Los Angeles-Hiroshima study. J Diabetes Investig (2013) 0.77
Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux. J Lipid Res (2016) 0.76
Untrained young men have dysfunctional HDL compared with strength-trained men irrespective of body weight status. J Appl Physiol (1985) (2013) 0.76
Increased Small Dense LDL and Decreased Paraoxonase Enzyme Activity Reveals Formation of an Atherogenic Risk in Streptozotocin-Induced Diabetic Guinea Pigs. J Diabetes Res (2013) 0.76
Tobacco Smoke Exposure Reduces Paraoxonase Activity in a Murine Model. Int J Biomed Sci (2017) 0.75
Dynamic changes of paraoxonase 1 activity towards paroxon and phenyl acetate during coronary artery surgery. BMC Cardiovasc Disord (2017) 0.75
Lecithin: cholesterol acyltransferase and na(+)-k(+)-ATPase activity in patients with breast cancer. J Breast Cancer (2013) 0.75
Further evidence that high-density lipoprotein is a chameleon-like lipoprotein. Eur Heart J (2015) 0.75
Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging. Front Pharmacol (2016) 0.75
The Mechanism of Proinflammatory HDL Generation in Sickle Cell Disease Is Linked to Cell-Free Hemoglobin via Haptoglobin. PLoS One (2016) 0.75
Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation. J Lipid Res (2015) 0.75
The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications. Coron Artery Dis (2016) 0.75
Proteome Dynamics Reveals Pro-Inflammatory Remodeling of Plasma Proteome in a Mouse Model of NAFLD. J Proteome Res (2016) 0.75
Antioxidants and Cardiovascular Risk Factors. Diseases (2016) 0.75
Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation (2001) 14.70
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg (2001) 11.58
Human lipoprotein lipase complementary DNA sequence. Science (1987) 9.50
KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science (1998) 7.32
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 7.08
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med (1999) 7.04
Essential role of Stat6 in IL-4 signalling. Nature (1996) 6.56
Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation (2001) 6.29
Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol (1996) 5.40
Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci U S A (1998) 5.21
Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A (1980) 4.66
Analysis of human chromosome 21: correlation of physical and cytogenetic maps; gene and CpG island distributions. EMBO J (1990) 4.49
Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A (1990) 4.34
Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem (1997) 3.91
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature (1998) 3.84
Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation (1995) 3.82
Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest (1990) 3.40
Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol (2000) 3.26
Type IV pilus of Myxococcus xanthus is a motility apparatus controlled by the frz chemosensory system. Curr Biol (2000) 3.24
Role of the Kv4.3 K+ channel in ventricular muscle. A molecular correlate for the transient outward current. Circ Res (1996) 3.23
Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest (1995) 3.23
Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest (1995) 3.14
Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum (2004) 3.12
Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature (1990) 3.11
Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest (1991) 3.07
Arthropod-borne viral infections of man in Nigeria, 1964-1970. Ann Trop Med Parasitol (1975) 2.98
Interactions between periodontal bacteria and human oral epithelial cells: Fusobacterium nucleatum adheres to and invades epithelial cells. Infect Immun (2000) 2.95
SOS3 function in plant salt tolerance requires N-myristoylation and calcium binding. Plant Cell (2000) 2.91
Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature (1993) 2.83
Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest (1999) 2.81
Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol (1997) 2.80
Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol (1999) 2.73
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature (1996) 2.71
TCR-Mediated internalization of peptide-MHC complexes acquired by T cells. Science (1999) 2.70
Metal-Based X-ray Contrast Media. Chem Rev (1999) 2.69
Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc Natl Acad Sci U S A (1987) 2.67
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem (2000) 2.65
The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol (1996) 2.56
Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res (2001) 2.55
The ars operon of Escherichia coli confers arsenical and antimonial resistance. J Bacteriol (1995) 2.52
Past adult lead exposure is linked to neurodegeneration measured by brain MRI. Neurology (2006) 2.52
Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice. Circulation (2000) 2.39
A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res (2001) 2.38
Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science (1993) 2.38
Treponema pallidum invades intercellular junctions of endothelial cell monolayers. Proc Natl Acad Sci U S A (1988) 2.37
Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk--a review of the literature. Eur J Clin Nutr (2009) 2.35
Induction of cyclin D1 overexpression by activated ras. Oncogene (1994) 2.35
Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev (2008) 2.32
Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb (1994) 2.31
A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J (2010) 2.30
Determinants of atherosclerosis susceptibility in the C3H and C57BL/6 mouse model: evidence for involvement of endothelial cells but not blood cells or cholesterol metabolism. Circ Res (2000) 2.28
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res (2000) 2.22
Glucose-6-phosphate dehydrogenase deficient red cells: resistance to infection by malarial parasites. Science (1969) 2.21
Treatment of fungal keratitis by penetrating keratoplasty. Br J Ophthalmol (2001) 2.20
The sequence of cDNA encoding lipoprotein lipase. A member of a lipase gene family. J Biol Chem (1987) 2.20
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol (1997) 2.17
Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest (2001) 2.16
Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity (2000) 2.16
Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice. Circ Res (2001) 2.14
Identification of a zinc finger protein that binds to the sterol regulatory element. Science (1989) 2.13
ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. Its cloning, expression, and characterization. J Biol Chem (1998) 2.13
The human and rodent intestinal fatty acid binding protein genes. A comparative analysis of their structure, expression, and linkage relationships. J Biol Chem (1987) 2.13
Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res (2001) 2.11
Increased sickling of parasitised erythrocytes as mechanism of resistance against malaria in the sickle-cell trait. Lancet (1970) 2.11
Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem (2001) 2.08
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res (2000) 2.05
Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol (1996) 2.04
Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc Natl Acad Sci U S A (1982) 2.04
Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem (2000) 2.02
The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure (1998) 2.02